75 related articles for article (PubMed ID: 7773608)
21. Atomic force microscopic analysis of the influence of the molecular weight of poly(L)lysine on the size of polyelectrolyte complexes formed with DNA.
Wolfert MA; Seymour LW
Gene Ther; 1996 Mar; 3(3):269-73. PubMed ID: 8646559
[TBL] [Abstract][Full Text] [Related]
22. Poly(amidoamine)s as potential endosomolytic polymers: evaluation in vitro and body distribution in normal and tumour-bearing animals.
Richardson S; Ferruti P; Duncan R
J Drug Target; 1999; 6(6):391-404. PubMed ID: 10937285
[TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points.
Kobayashi H; Le N; Kim IS; Kim MK; Pie JE; Drumm D; Paik DS; Waldmann TA; Paik CH; Carrasquillo JA
Cancer Res; 1999 Jan; 59(2):422-30. PubMed ID: 9927057
[TBL] [Abstract][Full Text] [Related]
24. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.
Kaminskas LM; Boyd BJ; Karellas P; Krippner GY; Lessene R; Kelly B; Porter CJ
Mol Pharm; 2008; 5(3):449-63. PubMed ID: 18393438
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of cellular uptake and gene transfer efficiency of pegylated poly-L-lysine compacted DNA: implications for cancer gene therapy.
Walsh M; Tangney M; O'Neill MJ; Larkin JO; Soden DM; McKenna SL; Darcy R; O'Sullivan GC; O'Driscoll CM
Mol Pharm; 2006; 3(6):644-53. PubMed ID: 17140252
[TBL] [Abstract][Full Text] [Related]
27. Structural advantage of dendritic poly(L-lysine) for gene delivery into cells.
Yamagata M; Kawano T; Shiba K; Mori T; Katayama Y; Niidome T
Bioorg Med Chem; 2007 Jan; 15(1):526-32. PubMed ID: 17035030
[TBL] [Abstract][Full Text] [Related]
28. [Labeling reactions of L-lysine and poly-L-lysine with 57Co and their distribution in normal and Ehrlich ascites tumor-bearing mice (author's transl)].
Motohashi N; Terao M; Mori I
Radioisotopes; 1981 Feb; 30(2):80-5. PubMed ID: 6794106
[TBL] [Abstract][Full Text] [Related]
29. Endothelial functional responses and increased vascular permeability induced by polycations.
Needham L; Hellewell PG; Williams TJ; Gordon JL
Lab Invest; 1988 Oct; 59(4):538-48. PubMed ID: 2459501
[TBL] [Abstract][Full Text] [Related]
30. Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol).
Zahr AS; Davis CA; Pishko MV
Langmuir; 2006 Sep; 22(19):8178-85. PubMed ID: 16952259
[TBL] [Abstract][Full Text] [Related]
31. Peptide-poly(L-lysine citramide) conjugates and their in vitro anti-HIV behavior.
Couffin-Hoarau AC; Aubertin AM; Boustta M; Schmidt S; Fehrentz JA; Martinez J; Vert M
Biomacromolecules; 2009 Apr; 10(4):865-76. PubMed ID: 19296658
[TBL] [Abstract][Full Text] [Related]
32. Superior cell delivery features of poly(ethylene glycol) incorporated alginate, chitosan, and poly-L-lysine microcapsules.
Haque T; Chen H; Ouyang W; Martoni C; Lawuyi B; Urbanska AM; Prakash S
Mol Pharm; 2005; 2(1):29-36. PubMed ID: 15804175
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy.
Lindegren S; Andersson H; Jacobsson L; Bäck T; Skarnemark G; Karlsson B
Bioconjug Chem; 2002; 13(3):502-9. PubMed ID: 12009939
[TBL] [Abstract][Full Text] [Related]
34. Carrier design: biodistribution of branched polypeptides with a poly(L-lysine) backbone.
Clegg JA; Hudecz F; Mezö G; Pimm MV; Szekerke M; Baldwin RW
Bioconjug Chem; 1990; 1(6):425-30. PubMed ID: 2099188
[TBL] [Abstract][Full Text] [Related]
35. Tissue-targeting ability of saccharide-poly(L-lysine) conjugates.
Gonsho A; Irie K; Susaki H; Iwasawa H; Okuno S; Sugawara T
Biol Pharm Bull; 1994 Feb; 17(2):275-82. PubMed ID: 8205127
[TBL] [Abstract][Full Text] [Related]
36. Use of N-terminal modified poly(L-lysine)-antibody conjugate as a carrier for targeted gene delivery in mouse lung endothelial cells.
Trubetskoy VS; Torchilin VP; Kennel SJ; Huang L
Bioconjug Chem; 1992; 3(4):323-7. PubMed ID: 1390987
[TBL] [Abstract][Full Text] [Related]
37. Comparative study on the in vitro cytotoxicity of linear, dendritic, and hyperbranched polylysine analogues.
Kadlecova Z; Baldi L; Hacker D; Wurm FM; Klok HA
Biomacromolecules; 2012 Oct; 13(10):3127-37. PubMed ID: 22931162
[TBL] [Abstract][Full Text] [Related]
38. Antineoplastic activity of poly(L-lysine) with some ascites tumor cells.
Arnold LJ; Dagan A; Gutheil J; Kaplan NO
Proc Natl Acad Sci U S A; 1979 Jul; 76(7):3246-50. PubMed ID: 291000
[TBL] [Abstract][Full Text] [Related]
39. Preference toward a polylysine enantiomer in inhibiting prions.
Jackson KS; Yeom J; Han Y; Bae Y; Ryou C
Amino Acids; 2013 Mar; 44(3):993-1000. PubMed ID: 23179088
[TBL] [Abstract][Full Text] [Related]
40. A conjugate of lactosaminated poly-L-lysine with adenine arabinoside monophosphate, administered to mice by intramuscular route, accomplishes a selective delivery of the drug to the liver.
Fiume L; Di Stefano G; Busi C; Mattioli A
Biochem Pharmacol; 1994 Feb; 47(4):643-50. PubMed ID: 7510478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
